How a local antibody maker scored its $1.75B deal with Celltrion

A Woburn-based biotech with a suite of antibodies targeting Covid-19 as well as immuno-oncology and ophthalmology indications has a new partnership with one of the largest pharmaceutical companies in the world. Here’s how it came together.